Advertisement

Topics

Genocea Biosciences Company Profile

19:18 EST 22nd November 2017 | BioPortfolio

Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. The Company’s proprietary T cell-directed antigen discovery program represents a broad platform with the potential to generate significant novel vaccines for multiple pathogens with high unmet medical need. Genocea is currently developing vaccines for Chlamydia trachomatis (a sexually transmitted disease agent causing an estimated 90 million cases worldwide), Streptococcus pneumoniae (pneumonia is the leading killer of children under the age of five worldwide), Herpes Simplex Virus Type 2 (45 million infected in the US)and Malaria (millions of cases each year) Genocea was recognized by BusinessWeek as one of the “World’s Most Intriguing Startups” for 2009. In 2008, Genocea was selected as “Best Vaccine Startup” at the World Vaccine Congress and was selected one of the 15 most exciting biotech startup companies by FierceBiotech. Genocea is backed by leading investors including Lux Capital Management, Polaris Venture Partners, S.R. One, the corporate venture arm of GlaxoSmithKline, Auriga Partners, Cycad Group, Morningside Ventures and Alexandria Real Estate Equities. Visit www.genocea.com for more information.


News Articles [601 Associated News Articles listed on BioPortfolio]

Pomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Genocea Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadline - GNCA

NEW YORK, NY / ACCESSWIRE / November 11, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Genocea Biosciences, Inc. ("Genocea" or the "Company") (NASDAQ: GNCA) and ...

IMPORTANT GENOCEA BIOSCIENCES, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces that a Securities Class Action Lawsuit has been Filed on Behalf of Investors who Purchased and Suffered Losses in Genocea Biosciences, Inc.

Lead Plaintiff Deadline is January 2, 2018 NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the Unit...

Amid Cash Crunch, Genocea to Dump Herpes Vaccine, Focus on Cancer Work

Genocea Biosciences was able to go from startup to publicly traded company, in part, because of the early progress it made developing an experimental vaccine for genital herpes. Yet the Cambridge, MA,...

Genocea Biosciences's (GNCA) Conference Call On Positive GEN-003 Phase 2b Results - Slideshow

Genocea Biosciences (GNCA) Presents At Stifel 2017 Healthcare Conference - Slideshow

Genocea Biosciences (GNCA) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow

Genocea Biosciences' (GNCA) CEO Chip Clark on Q3 2017 Results - Earnings Call Transcript

Stocks Under Scanner in the Biotech Space -- GlycoMimetics, Genocea Biosciences, Inotek Pharma, ...

If you want a Stock Review on GLYC, GNCA, ITEK, or LOXO then come over to http://dailystocktracker.com/register/and sign up for your free customized report Read more...

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

PubMed Articles [68 Associated PubMed Articles listed on BioPortfolio]

Draft Genome Sequences of Trichophyton rubrum CMCC(F)T1i and Trichophyton violaceum CMCC(F)T3l by Illumina 2000 and Pacific Biosciences.

One strain of Trichophyton rubrum CMCC(F)T1i (=CBS 139224) isolated from onychomycosis and one strain of Trichophyton violaceum CMCC(F)T3l (=CBS 141829) isolated from tinea capitis in China were whole...

Amnesia and criminal responsibility.

Front cover.

Contents list.

Front cover.

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

HepaStem Long-Term Safety Registry

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Bi...

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...

Validation of Decipher Test in African American Men With Prostate Cancer - VANDAAM

The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same a...

Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients

Cell-mediated immunity (CMI) and in particular T cells play a critical role in the rejection of transplanted organs. Thus, in transplant recipients a life-long and individualized immunosup...

Companies [344 Associated Companies listed on BioPortfolio]

Genocea Biosciences

Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. The Company’s proprietary T cell-directed antigen disc...

Genocea Biosciences, Inc.

Genocea Biosciences is a vaccine discovery and development company targeting major infectious diseases with high unmet medical needs, in which T cell responses help confer protect...

Genocea Biosciences Inc.

Genocea Biosciences is a vaccine discovery and development company targeting major infectious diseases with high unmet medical needs, in which T cell response helps confer protect...

Genocea Biosciences, Inc. 

Hydra Biosciences, Inc.

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, and develops drugs to treat pain, inflammation, anxiety and other diseases using...

More Information about "Genocea Biosciences" on BioPortfolio

We have published hundreds of Genocea Biosciences news stories on BioPortfolio along with dozens of Genocea Biosciences Clinical Trials and PubMed Articles about Genocea Biosciences for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genocea Biosciences Companies in our database. You can also find out about relevant Genocea Biosciences Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record